In 1989, Dr. Marc Mesnil obtained his PhD under the supervision of Dr. Yamasaki at the International Agency for Research on Cancer (Lyon, France) where he studied the involvement of gap junctions in carcinogenesis. He then pursued post-doctoral studies in the laboratory of Dr. Gilula at the Scripps Research Institute (La Jolla, California) where he confirmed that loss of gap junctional intercellular communication is a characteristic of cancer cells. From 1991, he went back to Dr. Yamasaki’s laboratory where he studied how gap junctions mediate anti-proliferation effect and also how they could be used to enhance the cytotoxicity of anticancer compounds by permitting their intercellular diffusion.
In 2000, Dr. Mesnil joined Dr. Giaume at the Collège de France (Paris, France) to study the effect of inflammation on astrocytic gap junctions; after a short time he was appointed as professor at the University of Poitiers (France). He developed a CNRS team focused on the study of gap junction involvement in brain tumor invasion and in metastatic bone targeting of prostate cancer cells. He is currently author and co-author of about 76 peer-reviewed articles.